BUSCETI, Maria Teresa
 Distribuzione geografica
Continente #
NA - Nord America 178
EU - Europa 77
AS - Asia 57
SA - Sud America 2
Continente sconosciuto - Info sul continente non disponibili 1
Totale 315
Nazione #
US - Stati Uniti d'America 170
SG - Singapore 43
IT - Italia 35
DE - Germania 21
CA - Canada 6
FI - Finlandia 6
CN - Cina 5
GB - Regno Unito 4
SE - Svezia 4
CZ - Repubblica Ceca 3
BR - Brasile 2
HK - Hong Kong 2
MX - Messico 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AT - Austria 1
BD - Bangladesh 1
BN - Brunei Darussalam 1
ES - Italia 1
IN - India 1
IQ - Iraq 1
NL - Olanda 1
PK - Pakistan 1
PT - Portogallo 1
TR - Turchia 1
VN - Vietnam 1
Totale 315
Città #
Singapore 35
Chandler 32
Santa Clara 15
Lawrence 9
Princeton 9
Milan 8
Munich 8
Turku 6
Redmond 4
Ashburn 3
London 3
Olomouc 3
Ottawa 3
Redwood City 3
Rome 3
Wilmington 3
Boston 2
Chicago 2
Des Moines 2
Guangzhou 2
Hong Kong 2
Los Angeles 2
Mexico City 2
Norwalk 2
Rapallo 2
San Francisco 2
Settingiano 2
Toronto 2
Acerra 1
Ankara 1
Baghdad 1
Bandar Seri Begawan 1
Beijing 1
Boardman 1
Brooklyn 1
Calgary 1
Dalian 1
Gaithersburg 1
Glasgow 1
Hanoi 1
Itapetininga 1
Karlsruhe 1
Mem Martins 1
Nagold 1
New York 1
Oak Lawn 1
Padova 1
Phoenix 1
Sindelfingen 1
The Bronx 1
Vado Ligure 1
Vienna 1
Zaragoza 1
Totale 196
Nome #
A case report of pneumomediastinum in a COVID-19 patient treated with high-flow nasal cannula and review of the literature: Is this a “spontaneous” complication? 48
Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose 38
Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma 36
Higher blood eosinophil levels after omalizumab treatment may be associated with poorer asthma outcomes 35
Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma 32
Asthma control in severe asthmatics under treatment with omalizumab: A cross-sectional observational study in Italy 31
Persistence of both reversible airway obstruction and higher blood eosinophils may predict lung function decline in severe asthma 31
New treatments for asthma: From the pathogenic role of prostaglandin D2 to the therapeutic effects of fevipiprant 29
Short-term evaluation of dupilumab effects in patients with severe asthma and nasal polyposis 22
Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma 13
Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study 12
Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps 8
Totale 335
Categoria #
all - tutte 4.413
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.413


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202120 0 0 3 0 9 1 2 0 2 2 0 1
2021/202226 1 0 0 4 2 0 4 3 3 4 5 0
2022/2023104 18 4 10 1 12 10 2 9 19 9 6 4
2023/202432 6 4 6 4 1 4 0 0 0 0 5 2
2024/2025111 17 1 1 1 15 23 2 2 4 0 24 21
2025/202620 20 0 0 0 0 0 0 0 0 0 0 0
Totale 335